Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Clin Cancer Res

Retrieve available abstracts of 123 articles:
HTML format

Single Articles

    February 2024
  1. LOU H, Cai H, Huang X, Li G, et al
    Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): a phase 2 study.
    Clin Cancer Res. 2024 Feb 19. doi: 10.1158/1078-0432.CCR-23-3162.
    PubMed     Abstract available

  2. BARTLETT JMS, Xu K, Wong J, Pond G, et al
    Validation of the prognostic performance of Breast Cancer Index (BCI) in hormone receptor-positive (HR+) postmenopausal breast cancer patients in the TEAM trial.
    Clin Cancer Res. 2024 Feb 12. doi: 10.1158/1078-0432.CCR-23-2436.
    PubMed     Abstract available

    January 2024
  3. WANG Y, Situ X, Cardenas H, Siu E, et al
    Preclinical evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer.
    Clin Cancer Res. 2024 Jan 17. doi: 10.1158/1078-0432.CCR-23-2368.
    PubMed     Abstract available

  4. LUKOVIC J, Pintilie M, Han K, Fyles AW, et al
    An immune gene expression risk score for distant metastases after radiotherapy for cervical cancer.
    Clin Cancer Res. 2024 Jan 5. doi: 10.1158/1078-0432.CCR-23-2085.
    PubMed     Abstract available

  5. OAKNIN A, Ghamande SA, Kasamatsu Y, Gil-Martin M, et al
    Phase 1 trial of first-line bintrafusp alfa in patients with locally advanced or persistent/recurrent/metastatic cervical cancer.
    Clin Cancer Res. 2024 Jan 2. doi: 10.1158/1078-0432.CCR-23-1829.
    PubMed     Abstract available

    December 2023
  6. TSANG ES, Gallinger S
    Deciphering the Pathways to PARP Sensitivity in Pancreatic Cancer.
    Clin Cancer Res. 2023;29:5005-5007.
    PubMed     Abstract available

  7. BROWN TJ, Yablonovitch A, Till JE, Yen J, et al
    The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib.
    Clin Cancer Res. 2023;29:5207-5216.
    PubMed     Abstract available

  8. WANG Y, Douville C, Chien YW, Wang BG, et al
    Aneuploidy Landscape in Precursors of Ovarian Cancer.
    Clin Cancer Res. 2023 Dec 1. doi: 10.1158/1078-0432.CCR-23-0932.
    PubMed     Abstract available

    November 2023
  9. DREW Y, Kim JW, Penson RT, O'Malley DM, et al
    Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naive Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-2249.
    PubMed     Abstract available

    Methodical Manipulation of the TME in Ovarian Cancer.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-2365.
    PubMed     Abstract available

  11. DENG N, Reyes-Uribe L, Fahrmann JF, Thoman WS, et al
    Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome.
    Clin Cancer Res. 2023;29:4361-4372.
    PubMed     Abstract available

    October 2023
  12. PATEL SP, Othus M, Chae YK, Dennis MJ, et al
    A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia.
    Clin Cancer Res. 2023 Oct 26. doi: 10.1158/1078-0432.CCR-23-2293.
    PubMed     Abstract available

  13. BUCKLEY DN, Lewinger JP, Gooden G, Spillman M, et al
    OvaPrint - a cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer.
    Clin Cancer Res. 2023 Oct 9. doi: 10.1158/1078-0432.CCR-23-1197.
    PubMed     Abstract available

    September 2023
  14. JAMIESON A, Vermij L, Kramer CJH, Jobsen JJ, et al
    Clinical Behavior and Molecular Landscape of Stage I p53-abnormal Low-Grade Endometrioid Endometrial Carcinomas.
    Clin Cancer Res. 2023 Sep 29. doi: 10.1158/1078-0432.CCR-23-1397.
    PubMed     Abstract available

  15. LEMAN R, Muller E, Legros A, Goardon N, et al
    Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer.
    Clin Cancer Res. 2023 Sep 26:OF1-OF11. doi: 10.1158/1078-0432.CCR-23-0898.
    PubMed     Abstract available

  16. SANFILIPPO R, Sbaraglia M, Fabbroni C, Croce S, et al
    Low-grade uterine Leiomyosarcoma is highly sensitive to hormonal treatment.
    Clin Cancer Res. 2023 Sep 12. doi: 10.1158/1078-0432.CCR-23-0692.
    PubMed     Abstract available

  17. JANGRA R, Dhani NC
    Re-routing the GPS directing immunotherapy in endometrial cancer.
    Clin Cancer Res. 2023 Sep 12. doi: 10.1158/1078-0432.CCR-23-1953.
    PubMed     Abstract available

    August 2023
  18. FRIEDMAN CF, Ravichandran V, Miller K, Vanderbilt C, et al
    Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets.
    Clin Cancer Res. 2023 Aug 29:CCR-23-1078. doi: 10.1158/1078-0432.CCR-23-1078.
    PubMed     Abstract available

  19. GRISHAM RN, Vergote I, Banerjee S, Drill E, et al
    Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
    Clin Cancer Res. 2023 Aug 15:CCR-23-0621. doi: 10.1158/1078-0432.CCR-23-0621.
    PubMed     Abstract available

  20. TAVIRA B, Iscar T, Manso L, Santaballa A, et al
    Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).
    Clin Cancer Res. 2023 Aug 1:CCR-23-0771. doi: 10.1158/1078-0432.CCR-23-0771.
    PubMed     Abstract available

    July 2023
  21. COSTAS L, Onieva I, Pelegrina B, Marin F, et al
    Evaluation of somatic mutations in urine samples as a non-invasive method for the detection and molecular classification of endometrial cancer.
    Clin Cancer Res. 2023 Jul 13:CCR-23-0367. doi: 10.1158/1078-0432.CCR-23-0367.
    PubMed     Abstract available

  22. DOE-TETTEH SA, Camp SY, Reales D, Crowdis J, et al
    Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach.
    Clin Cancer Res. 2023;29:2445-2455.
    PubMed     Abstract available

    June 2023
  23. OAKNIN A, Pothuri B, Gilbert L, Sabatier R, et al
    Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
    Clin Cancer Res. 2023 Jun 26:CCR-22-3915. doi: 10.1158/1078-0432.CCR-22-3915.
    PubMed     Abstract available

  24. GARG V, Oza AM
    Assessment of Homologous Recombination Deficiency in Ovarian Cancer.
    Clin Cancer Res. 2023 Jun 22:CCR-23-0563. doi: 10.1158/1078-0432.CCR-23-0563.
    PubMed     Abstract available

  25. HEINZE K, Cairns ES, Thornton S, Harris B, et al
    The prognostic effect of immune cell infiltration depends on molecular subtype in Endometrioid Ovarian Carcinomas.
    Clin Cancer Res. 2023 Jun 20:CCR-22-3815. doi: 10.1158/1078-0432.CCR-22-3815.
    PubMed     Abstract available

  26. LHEUREUX S, Prokopec SD, Oldfield LE, Gonzalez-Ochoa E, et al
    Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression.
    Clin Cancer Res. 2023 Jun 16:CCR-23-0797. doi: 10.1158/1078-0432.CCR-23-0797.
    PubMed     Abstract available

  27. MCDERMOTT MSJ, O'Brien NA, Hoffstrom B, Gong K, et al
    Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
    Clin Cancer Res. 2023;29:2131-2143.
    PubMed     Abstract available

  28. CHANDARLAPATY S, Dickler MN, Perez Fidalgo JA, Villanueva-Vazquez R, et al
    An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer.
    Clin Cancer Res. 2023 Jun 1:CCR-23-0011. doi: 10.1158/1078-0432.CCR-23-0011.
    PubMed     Abstract available

  29. SCHWARTZ GN, Kaufman PA, Giridhar KV, Marotti JD, et al
    Alternating 17beta-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer.
    Clin Cancer Res. 2023 Jun 1:OF1-OF7. doi: 10.1158/1078-0432.CCR-23-0112.
    PubMed     Abstract available

    May 2023
  30. DILAWARI A, Shah M, Ison G, Gittleman H, et al
    FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRalpha-positive, Platinum-Resistant Ovarian Cancer.
    Clin Cancer Res. 2023 May 22:CCR-23-0991. doi: 10.1158/1078-0432.CCR-23-0991.
    PubMed     Abstract available

    An attempt to stretch the benefit: Re-challenge with PARP inhibitors in ovarian cancer.
    Clin Cancer Res. 2023 May 16:CCR-23-0652. doi: 10.1158/1078-0432.CCR-23-0652.
    PubMed     Abstract available

  32. SCHWARTZ GN, Kaufman PA, Giridhar KV, Marotti JD, et al
    Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer.
    Clin Cancer Res. 2023 May 15:CCR-23-0112. doi: 10.1158/1078-0432.CCR-23-0112.
    PubMed     Abstract available

  33. DORIGO O, Oza AM, Pejovic T, Ghatage P, et al
    Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase 2 trial.
    Clin Cancer Res. 2023 May 1:CCR-22-2595. doi: 10.1158/1078-0432.CCR-22-2595.
    PubMed     Abstract available

    April 2023
  34. COMPADRE AJ, van Biljon LN, Valentine MC, Llop-Guevara A, et al
    RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer.
    Clin Cancer Res. 2023 Apr 25:CCR-22-3335. doi: 10.1158/1078-0432.CCR-22-3335.
    PubMed     Abstract available

  35. WETHINGTON SL, Shah PD, Martin L, Tanyi JL, et al
    Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer.
    Clin Cancer Res. 2023 Apr 25:CCR-22-2444. doi: 10.1158/1078-0432.CCR-22-2444.
    PubMed     Abstract available

  36. BLANC-DURAND F, Tang R, Pommier M, Nashvi M, et al
    Clinical relevance of BRCA1 promoter methylation testing in ovarian cancer patients.
    Clin Cancer Res. 2023 Apr 17:CCR-22-3328. doi: 10.1158/1078-0432.CCR-22-3328.
    PubMed     Abstract available

  37. KIM YN, Shim Y, Seo J, Choi Z, et al
    Investigation of poly ADP-ribose polymerase inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-mutated ovarian cancer.
    Clin Cancer Res. 2023 Apr 17:CCR-22-3715. doi: 10.1158/1078-0432.CCR-22-3715.
    PubMed     Abstract available

  38. LIU YL, Zamarin D
    Shedding Light on PARP Inhibitor Response through Functional Imaging.
    Clin Cancer Res. 2023;29:1384-1386.
    PubMed     Abstract available

    March 2023
  39. YAGISHITA S, Nishikawa T, Yoshida H, Shintani D, et al
    Co-clinical study of [fam-] trastuzumab deruxtecan (DS8201a) in patient-derived xenograft models of uterine carcinosarcoma and its association with clinical efficacy.
    Clin Cancer Res. 2023 Mar 28:CCR-22-3861. doi: 10.1158/1078-0432.CCR-22-3861.
    PubMed     Abstract available

  40. BATALINI F, Mina LA, Mina A
    Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Letter.
    Clin Cancer Res. 2023;29:1157.

  41. MARMOUSET V, Morice PM, Pages A, Leary A, et al
    Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Response.
    Clin Cancer Res. 2023;29:1158-1159.

    February 2023
  42. AL-RAWI DH, Rusk N, Friedman CF
    The Search for Genomic Biomarkers of Response to Immunotherapy in Ovarian Cancer.
    Clin Cancer Res. 2023 Feb 24:CCR-23-0048. doi: 10.1158/1078-0432.CCR-23-0048.
    PubMed     Abstract available

  43. PIKKUSAARI S, Tumiati M, Virtanen A, Oikkonen J, et al
    Functional homologous recombination assay on FFPE specimens of advanced high-grade serous ovarian cancer predicts clinical outcomes.
    Clin Cancer Res. 2023 Feb 20:CCR-22-3156. doi: 10.1158/1078-0432.CCR-22-3156.
    PubMed     Abstract available

  44. MORGAN RD, Clamp AR, White DJ, Price M, et al
    Multi-maintenance olaparib therapy in relapsed, germline BRCA1/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial.
    Clin Cancer Res. 2023 Feb 17:CCR-22-3282. doi: 10.1158/1078-0432.CCR-22-3282.
    PubMed     Abstract available

  45. COLE AJ, Panesso-Gomez S, Shah JS, Ebai T, et al
    Quiescent ovarian cancer cells secrete follistatin to induce chemotherapy resistance in surrounding cells in response to chemotherapy.
    Clin Cancer Res. 2023 Feb 16:CCR-22-2254. doi: 10.1158/1078-0432.CCR-22-2254.
    PubMed     Abstract available

    January 2023
  46. GREEN DS, Ning F, Duemler A, Myers TG, et al
    Correction: Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial.
    Clin Cancer Res. 2023;29:501.

  47. WAINBERG ZA, Singh AS, Konecny GE, McCann KE, et al
    Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy.
    Clin Cancer Res. 2023;29:40-49.
    PubMed     Abstract available

  48. LANDEN CN, Molinero L, Hamidi H, Sehouli J, et al
    Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.
    Clin Cancer Res. 2023 Jan 3:CCR-22-2032. doi: 10.1158/1078-0432.CCR-22-2032.
    PubMed     Abstract available

    December 2022
  49. LYNG H, Skipar K, Hompland T
    Targeted Therapy on the Screen: Do We Hit the Target?
    Clin Cancer Res. 2022;28:5233-5234.
    PubMed     Abstract available

  50. MARMOUSET V, Decroocq J, Garciaz S, Etienne G, et al
    Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
    Clin Cancer Res. 2022;28:5211-5220.
    PubMed     Abstract available

    November 2022
  51. PANTEL AR, Gitto SB, Makvandi M, Kim H, et al
    [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a pilot study.
    Clin Cancer Res. 2022 Nov 28:CCR-22-1602. doi: 10.1158/1078-0432.CCR-22-1602.
    PubMed     Abstract available

  52. CHOW S, Dorigo O
    Monocytes - A Promising New TRAIL in Ovarian Cancer Cell Therapy.
    Clin Cancer Res. 2022 Nov 16. pii: 710895. doi: 10.1158/1078-0432.CCR-22-2877.
    PubMed     Abstract available

  53. HILLEMANNS P, Denecke A, Woelber L, Bohmer G, et al
    A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I/IIa Trial.
    Clin Cancer Res. 2022;28:4885-4892.
    PubMed     Abstract available

  54. GRANT BM, Pugh TJ, Oza AM
    Molecular monitoring in endometrial cancer - ready for prime time?
    Clin Cancer Res. 2022 Nov 10. pii: 710550. doi: 10.1158/1078-0432.CCR-22-2781.
    PubMed     Abstract available

    October 2022
  55. ELIA A, Saldain L, Vanzulli SI, Helguero LA, et al
    Beneficial effects of mifepristone treatment in breast cancer patients selected by the progesterone receptor isoform ratio: Results from the MIPRA trial.
    Clin Cancer Res. 2022 Oct 21. pii: 709943. doi: 10.1158/1078-0432.CCR-22-2060.
    PubMed     Abstract available

  56. GHOSH S, Mazumdar T, Xu W, Powell RT, et al
    Combined TRIP13 and Aurora Kinase Inhibition Induces Apoptosis in Human Papillomavirus-Driven Cancers.
    Clin Cancer Res. 2022;28:4479-4493.
    PubMed     Abstract available

    Taking the Road Less Traveled: Following Molecular Trail Markers.
    Clin Cancer Res. 2022;28:4357-4359.
    PubMed     Abstract available

  58. MEAGHER NS, Gorringe KL, Wakefield MJ, Bolithon A, et al
    Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes.
    Clin Cancer Res. 2022 Oct 12. pii: 709665. doi: 10.1158/1078-0432.CCR-22-1206.
    PubMed     Abstract available

    September 2022
  59. AN J, Tang J, Li BX, Xiong H, et al
    Efficacy and Safety of the Anti-PD-L1 Monoclonal Antibody Socazolimab for Recurrent or Metastatic Cervical Cancer: A Phase I Dose-Escalation and Expansion Study.
    Clin Cancer Res. 2022 Sep 22. pii: 709354. doi: 10.1158/1078-0432.CCR-22-1280.
    PubMed     Abstract available

  60. GREEN DS, Ning F, Duemler A, Myers TG, et al
    Intraperitoneal monocytes and interferons as a novel cellular immunotherapy for ovarian cancer: mechanistic characterization and results of a phase I clinical trial.
    Clin Cancer Res. 2022 Sep 13. pii: 709187. doi: 10.1158/1078-0432.CCR-22-1893.
    PubMed     Abstract available

    Multi-omics uncovering different faces of Clear Cell Ovarian Cancer.
    Clin Cancer Res. 2022 Sep 12. pii: 709169. doi: 10.1158/1078-0432.CCR-22-2365.
    PubMed     Abstract available

  62. BATALINI F, Gulhan DC, Mao V, Tran A, et al
    Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers.
    Clin Cancer Res. 2022 Sep 1. pii: 708955. doi: 10.1158/1078-0432.CCR-22-0749.
    PubMed     Abstract available

    August 2022
  63. CONSTANTINIDOU A, Marcou Y, Toss MS, Simmons T, et al
    Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-positive, HER2-negative Primary Breast Cancer.
    Clin Cancer Res. 2022 Aug 31. pii: 708058. doi: 10.1158/1078-0432.CCR-22-0619.
    PubMed     Abstract available

  64. IRAJIZAD E, Han CY, Celestino J, Wu R, et al
    A blood-based metabolite panel for distinguishing ovarian cancer from benign pelvic masses.
    Clin Cancer Res. 2022 Aug 29. pii: 708818. doi: 10.1158/1078-0432.CCR-22-1113.
    PubMed     Abstract available

  65. HAN K, Fyles A, Shek T, Croke J, et al
    A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer.
    Clin Cancer Res. 2022 Aug 29. pii: 708819. doi: 10.1158/1078-0432.CCR-22-1665.
    PubMed     Abstract available

  66. ASHLEY CW, Selenica P, Patel J, Wu M, et al
    High-sensitivity mutation analysis of cell-free DNA for disease monitoring in endometrial cancer.
    Clin Cancer Res. 2022 Aug 25. pii: 708712. doi: 10.1158/1078-0432.CCR-22-1134.
    PubMed     Abstract available

  67. WIMBERGER P, Gerber MJ, Pfisterer J, Erdmann K, et al
    Bevacizumab may differentially improve prognosis of advanced ovarian cancer patients with low expression of VEGF-A165b, an anti-angiogenic VEGF-A splice variant.
    Clin Cancer Res. 2022 Aug 24. pii: 708584. doi: 10.1158/1078-0432.CCR-22-1326.
    PubMed     Abstract available

  68. BANERJEE S, Michalarea V, Ang JE, Ingles Garces A, et al
    A phase I trial of CT900, a novel alpha-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer.
    Clin Cancer Res. 2022 Aug 19. pii: 708154. doi: 10.1158/1078-0432.CCR-22-1268.
    PubMed     Abstract available

  69. MILLER KM, Friedman CF
    Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer.
    Clin Cancer Res. 2022 Aug 10. pii: 707611. doi: 10.1158/1078-0432.CCR-22-1779.
    PubMed     Abstract available

  70. SERRA V, Wang AT, Castroviejo-Bermejo M, Polanska UM, et al
    Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance.
    Clin Cancer Res. 2022 Aug 3. pii: 707431. doi: 10.1158/1078-0432.CCR-22-0568.
    PubMed     Abstract available

  71. SINGER CF, Holst F, Steurer S, Burandt EC, et al
    Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer.
    Clin Cancer Res. 2022 Aug 3:OF1-OF9. doi: 10.1158/1078-0432.CCR-21-4328.
    PubMed     Abstract available

  72. LEE JM, Moore RG, Ghamande S, Park MS, et al
    Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation and with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.
    Clin Cancer Res. 2022 Aug 2. pii: 707411. doi: 10.1158/1078-0432.CCR-21-1733.
    PubMed     Abstract available

    July 2022
  73. MANNING-GEIST BL, Liu YL, Devereaux KA, Da Cruz Paula A, et al
    Microsatellite instability-high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles.
    Clin Cancer Res. 2022 Jul 18. pii: 707055. doi: 10.1158/1078-0432.CCR-22-0713.
    PubMed     Abstract available

  74. BOLTON KL, Chen D, Corona de la Fuente RI, Fu Z, et al
    Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes.
    Clin Cancer Res. 2022 Jul 11. pii: 706955. doi: 10.1158/1078-0432.CCR-21-3817.
    PubMed     Abstract available

  75. FISHER NC, Byrne RM, Leslie H, Wood C, et al
    Biological misinterpretation of transcriptional signatures in tumour samples can unknowingly undermine mechanistic understanding and faithful alignment with preclinical data.
    Clin Cancer Res. 2022 Jul 6. pii: 706888. doi: 10.1158/1078-0432.CCR-22-1102.
    PubMed     Abstract available

  76. MARIN-JIMENEZ JA, Garcia-Mulero S, Matias-Guiu X, Piulats JM, et al
    Facts and hopes in immunotherapy of endometrial cancer.
    Clin Cancer Res. 2022 Jul 5. pii: 706852. doi: 10.1158/1078-0432.CCR-21-1564.
    PubMed     Abstract available

    June 2022
  77. NOH JJ, Cho YJ, Ryu JY, Choi JJ, et al
    Anti-cancer activity of the combination of cabozantinib and temozolomide in uterine sarcoma.
    Clin Cancer Res. 2022 Jun 21. pii: 705009. doi: 10.1158/1078-0432.CCR-22-0985.
    PubMed     Abstract available

  78. JOHNSON M, Dudek AZ, Sukari A, Call J, et al
    ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study.
    Clin Cancer Res. 2022;28:2517-2526.
    PubMed     Abstract available

  79. HOLLIS RL, Meynert AM, Michie CO, Rye T, et al
    Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification.
    Clin Cancer Res. 2022 Jun 13. pii: 704888. doi: 10.1158/1078-0432.CCR-22-0368.
    PubMed     Abstract available

  80. XU J, Fang Y, Chen K, Li S, et al
    Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer.
    Clin Cancer Res. 2022 Jun 8. pii: 704811. doi: 10.1158/1078-0432.CCR-22-0296.
    PubMed     Abstract available

  81. FENG J, Tang D, Wang J, Zhou Q, et al
    SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-beta, for recurrent or metastatic cervical cancer: a clinical expansion cohort of phase 1 study.
    Clin Cancer Res. 2022 Jun 2. pii: 699316. doi: 10.1158/1078-0432.CCR-22-0346.
    PubMed     Abstract available

  82. BYCHKOVSKY BL, Li T, Sotelo J, Tayob N, et al
    Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.
    Clin Cancer Res. 2022;28:2349-2360.
    PubMed     Abstract available

  83. NICUM S, Blagden SP
    PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.
    Clin Cancer Res. 2022;28:2201-2203.
    PubMed     Abstract available

    May 2022
  84. ARANDA F, Eguren-Santamaria I, Bella A, Berraondo P, et al
    Revisiting Intracavitary Immunotherapy of Cancer.
    Clin Cancer Res. 2022;28:1993-1995.
    PubMed     Abstract available

  85. FUCIKOVA J, Hensler M, Kasikova L, Lanickova T, et al
    An autologous dendritic cell vaccine promotes anticancer immunity in ovarian cancer patients with low mutational burden and cold tumors.
    Clin Cancer Res. 2022 May 10. pii: 696491. doi: 10.1158/1078-0432.CCR-21-4413.
    PubMed     Abstract available

    April 2022
  86. YANG SYC, Pugh TJ, Oza AM
    Double trouble: whole genome doubling distinguishes early from late ovarian cancer.
    Clin Cancer Res. 2022 Apr 27. pii: 694785. doi: 10.1158/1078-0432.CCR-22-0336.
    PubMed     Abstract available

  87. MANNING-GEIST B, Gordhandas S, Liu YL, Zhou Q, et al
    MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma.
    Clin Cancer Res. 2022 Apr 20. pii: 694634. doi: 10.1158/1078-0432.CCR-21-4183.
    PubMed     Abstract available

  88. LIU M, Tayob N, Penter L, Sellars M, et al
    Improved T cell immunity following neoadjuvant chemotherapy in ovarian cancer.
    Clin Cancer Res. 2022 Apr 20. pii: 694633. doi: 10.1158/1078-0432.CCR-21-2834.
    PubMed     Abstract available

  89. CHENG Z, Mirza H, Ennis DP, Smith P, et al
    The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.
    Clin Cancer Res. 2022 Apr 10:OF1-OF12. doi: 10.1158/1078-0432.CCR-21-1643.
    PubMed     Abstract available

  90. LIM JSJ, Wong ALA, Ow SGW, Ngoi NYL, et al
    Phase Ib/II dose expansion study of lenvatinib combined with letrozole in post-menopausal women with hormone receptor positive breast cancer.
    Clin Cancer Res. 2022 Apr 1. pii: 694118. doi: 10.1158/1078-0432.CCR-21-4179.
    PubMed     Abstract available

  91. AREND RC, Scalise CB, Gordon ER, Davis AM, et al
    Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC.
    Clin Cancer Res. 2022;28:1433-1445.
    PubMed     Abstract available

    March 2022
  92. YOSHIDA K, Yokoi A, Yamamoto T, Hayashi Y, et al
    Aberrant activation of cell cycle-related kinases and the potential therapeutic impact of PLK1 or CHEK1 inhibition in uterine leiomyosarcoma.
    Clin Cancer Res. 2022 Mar 18. pii: 682165. doi: 10.1158/1078-0432.CCR-22-0100.
    PubMed     Abstract available

  93. VAN DEN HELDER R, Steenbergen RDM, van Splunter AP, Mom CH, et al
    Clin Cancer Res. 2022 Mar 10. pii: 682143. doi: 10.1158/1078-0432.CCR-21-3710.
    PubMed     Abstract available

    February 2022
  94. DIGKLIA A, Coukos G, Homicsko K
    Trabectedin and Durvalumab Combination is Feasible - and Active in Relapsing Ovarian Cancer.
    Clin Cancer Res. 2022 Feb 17. pii: 681578. doi: 10.1158/1078-0432.CCR-21-4592.
    PubMed     Abstract available

  95. GAO Q, Zhu J, Zhao W, Huang Y, et al
    Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).
    Clin Cancer Res. 2022 Feb 7. pii: 1078-0432.CCR-21-3023.
    PubMed     Abstract available

  96. SERRITELLA AV, Shevrin D, Heath EI, Wade JL, et al
    Phase I/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2022 Feb 2. pii: 1078-0432.CCR-21-4049.
    PubMed     Abstract available

    January 2022
  97. ORR B, Mahdi H, Fang Y, Strange M, et al
    Phase I trial combining chemokine-targeting with loco-regional chemo-immunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity.
    Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-3659.
    PubMed     Abstract available

  98. VOUGIOUKLAKIS T, Zhu K, Vasudevaraja V, Serrano J, et al
    Integrated analysis of ovarian juvenile granulosa cell tumors reveals distinct epigenetic signatures and recurrent TERT rearrangements.
    Clin Cancer Res. 2022 Jan 14. pii: 1078-0432.CCR-21-3394.
    PubMed     Abstract available

  99. GARCIA-SAENZ JA, Martinez-Janez N, Cubedo R, Jerez Y, et al
    Sapanisertib Plus Fulvestrant in Post-Menopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer After Progression on Aromatase Inhibitor.
    Clin Cancer Res. 2022 Jan 3. pii: 1078-0432.CCR-21-2652.
    PubMed     Abstract available

    December 2021
  100. TOULMONDE M, Brahmi M, Giraud A, Chakiba C, et al
    Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-2258.
    PubMed     Abstract available

  101. SHARMA SK, Mack KN, Piersigilli A, Pourat J, et al
    ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.
    Clin Cancer Res. 2021 Dec 14. pii: 1078-0432.CCR-21-1798.
    PubMed     Abstract available

    November 2021
  102. WU X, Zhu J, Wang J, Lin ZQ, et al
    Pamiparib Monotherapy for Patients With Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated With at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study.
    Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-1186.
    PubMed     Abstract available

  103. VAN DER WIJNGAART H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, et al
    Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.
    Clin Cancer Res. 2021;27:6106-6114.
    PubMed     Abstract available

    October 2021
  104. ARORA S, Narayan P, Ison G, Berman T, et al
    U.S. FDA Drug Approvals for Gynecological Malignancies - A Decade in Review.
    Clin Cancer Res. 2021 Oct 28. pii: 1078-0432.CCR-21-2599.
    PubMed     Abstract available

  105. MOORE KN, Chambers SK, Hamilton EP, Chen LM, et al
    Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: an Open-Label, Four-Arm, Phase II Study.
    Clin Cancer Res. 2021 Oct 13. pii: 1078-0432.CCR-21-0158.
    PubMed     Abstract available

  106. TIAN L, Xu B, Teng KY, Song M, et al
    Targeting Fc receptor-mediated effects and the "don't eat me" signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer.
    Clin Cancer Res. 2021 Oct 13. pii: 1078-0432.CCR-21-1248.
    PubMed     Abstract available

    September 2021
  107. SCHOUTEN PC, Richters LK, Vis DJ, Kommoss S, et al
    Ovarian cancer specific BRCA-like copy number aberration classifiers detect mutations associated with homologous recombination deficiency in the AGO-TR1 trial.
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1673.
    PubMed     Abstract available

  108. DO KT, Kochupurakkal B, Kelland S, de Jonge A, et al
    Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
    Clin Cancer Res. 2021;27:4710-4716.
    PubMed     Abstract available

    August 2021
  109. MAITLAND ML, Sachdev JC, Sharma MR, Moreno V, et al
    First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
    Clin Cancer Res. 2021;27:4511-4520.
    PubMed     Abstract available

  110. WILLIAMSON CW, Zamarin D, Mayadev J
    Standardized Uptake Value Illuminates Tumor Inflammation and Treatment Response.
    Clin Cancer Res. 2021;27:4136-4138.
    PubMed     Abstract available

    July 2021
  111. MONDINI M, Deutsch E
    (Chemo)Radiotherapy-Immunotherapy Combinations: Time to Get Tailored?
    Clin Cancer Res. 2021;27:3815-3817.
    PubMed     Abstract available

    January 2021
  112. HONG B, Chapa V, Saini U, Modgil P, et al
    Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity.
    Clin Cancer Res. 2021;27:542-553.
    PubMed     Abstract available

    September 2020
  113. JIN ZH, Tsuji AB, Degardin M, Sugyo A, et al
    Radiotheranostic Agent (64)Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer.
    Clin Cancer Res. 2020 Sep 15. pii: 1078-0432.CCR-20-1205.
    PubMed     Abstract available

  114. JORDAN K, Sikora MJ, Slansky JE, Minic A, et al
    The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval.
    Clin Cancer Res. 2020 Sep 14. pii: 1078-0432.CCR-20-1762.
    PubMed     Abstract available

    August 2020
  115. DA SILVA DM, Enserro DM, Mayadev J, Skeate JG, et al
    Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929).
    Clin Cancer Res. 2020 Aug 18. pii: 1078-0432.CCR-20-0776.
    PubMed     Abstract available

    July 2020
  116. MORONEY JW, Powderly J, Lieu CH, Bendell JC, et al
    Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study.
    Clin Cancer Res. 2020 Jul 28. pii: 1078-0432.CCR-20-0477.
    PubMed     Abstract available

  117. OZA AM, Estevez-Diz MDP, Grischke EM, Hall M, et al
    A biomarker-enriched, randomized Phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer.
    Clin Cancer Res. 2020 Jul 1. pii: 1078-0432.CCR-20-0219.
    PubMed     Abstract available

    May 2020
  118. LHEUREUX S, Oaknin A, Garg S, Bruce JP, et al
    EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    Clin Cancer Res. 2020 May 22. pii: 1078-0432.CCR-19-4121.
    PubMed     Abstract available

  119. JI JX, Cochrane DR, Tessier-Cloutier B, Chen SY, et al
    Arginine depletion therapy with ADI-PEG20 limits tumor growth in argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type.
    Clin Cancer Res. 2020 May 14. pii: 1078-0432.CCR-19-1905.
    PubMed     Abstract available

  120. LAMPERT EJ, Zimmer AS, Padget MR, Cimino-Mathews A, et al
    Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study.
    Clin Cancer Res. 2020 May 12. pii: 1078-0432.CCR-20-0056.
    PubMed     Abstract available

    April 2020
  121. LI J, Pan C, Boese AC, Kang J, et al
    DGKA provides platinum resistance in ovarian cancer through activation of cJUN-WEE1 signaling.
    Clin Cancer Res. 2020 Apr 27. pii: 1078-0432.CCR-19-3790.
    PubMed     Abstract available

    March 2020
  122. YOU B, Robelin P, Tod M, Louvet C, et al
    CA-125 ELIMination rate constant K (KELIM) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial.
    Clin Cancer Res. 2020 Mar 24. pii: 1078-0432.CCR-20-0054.
    PubMed     Abstract available

    February 2020
  123. HARRIS RS, Serebrenik AA, Argyris P, Jarvis MC, et al
    The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer.
    Clin Cancer Res. 2020 Feb 14. pii: 1078-0432.CCR-19-2786.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.